Skip to the page

Data / Drug companies / Sola Pharmaceuticals, LLC

Sola Pharmaceuticals, LLC: 36 products in the FDA NDC directory, labeler code 70512

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Sola Pharmaceuticals, LLC (labeler code 70512) lists 36 products in the FDA National Drug Code Directory, covering 25 finished drugs by generic name. By type: 26 prescription drugs, 10 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on December 3, 2025.

The request: Watch Sola Pharmaceuticals, LLC (FDA labeler code 70512): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
70512
Products in commercial distribution
36
Packages
46
Finished drugs by generic name
25
Prescription products
26
Over the counter products
10
Flagged as original packager
35 of 35 products that carry the flag
Started marketing in the last 12 months
2
Earliest marketing start
May 25, 2017
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)2672.2%
Over the counter monograph drugs822.2%
New drug applications (NDA)25.6%

Products by type

TypeProductsShare
Prescription drugs2672.2%
Over the counter drugs1027.8%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Patch719.4%
Solution/ drops411.1%
Injection411.1%
Injection, solution411.1%
Tablet411.1%
Solution38.3%
Tablet, film coated38.3%
Gel25.6%
Capsule, delayed release25.6%
Capsule25.6%
Tablet, delayed release12.8%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Oxaprozin70512-787CapsuleNew drug applications (NDA)December 3, 2025
Diclofenac Sodium70512-784Tablet, delayed releaseGeneric drugs (ANDA)November 14, 2025
Coxanto70512-814CapsuleNew drug applications (NDA)November 3, 2025
Cyclobenzaprine Hydrochloride70512-872Tablet, film coatedGeneric drugs (ANDA)July 31, 2025
Baclofen70512-782TabletGeneric drugs (ANDA)March 21, 2025
Ibuprofen70512-794TabletGeneric drugs (ANDA)February 14, 2025
Ropivacaine hydrochloride70512-798Injection, solutionGeneric drugs (ANDA)December 1, 2024
Ropivacaine hydrochloride70512-797Injection, solutionGeneric drugs (ANDA)December 1, 2024
Ibuprofen70512-780TabletGeneric drugs (ANDA)December 1, 2024
Diclofenac Potassium70512-900Tablet, film coatedGeneric drugs (ANDA)November 1, 2024
Ketorolac Tromethamine70512-844InjectionGeneric drugs (ANDA)October 22, 2024
Diclofenac Potassium70512-750Tablet, film coatedGeneric drugs (ANDA)October 21, 2024
Phenylephrine Hydrochloride70512-866Solution/ dropsGeneric drugs (ANDA)June 1, 2024
Phenylephrine Hydrochloride70512-865Solution/ dropsGeneric drugs (ANDA)June 1, 2024
Ofloxacin70512-793Solution/ dropsGeneric drugs (ANDA)April 30, 2024
Ketorolac Tromethamine70512-790SolutionGeneric drugs (ANDA)April 15, 2024
Lidocaine 4% Patch70512-812PatchOver the counter monograph drugsOctober 12, 2023
Carboprost tromethamine70512-859Injection, solutionGeneric drugs (ANDA)September 25, 2023
Ketorolac Tromethamine70512-843InjectionGeneric drugs (ANDA)July 1, 2023
Ketorolac Tromethamine70512-842InjectionGeneric drugs (ANDA)July 1, 2023
Diclofenac Sodium70512-810SolutionGeneric drugs (ANDA)July 1, 2023
Cabergoline70512-860TabletGeneric drugs (ANDA)May 8, 2023
Dimethyl Fumarate70512-853Capsule, delayed releaseGeneric drugs (ANDA)January 31, 2023
Dimethyl Fumarate70512-852Capsule, delayed releaseGeneric drugs (ANDA)January 31, 2023
Triceptin70512-017PatchOver the counter monograph drugsDecember 5, 2022

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.